Emerging Targets for Hematopoietic Cell Transplantation (HCT): Genetic Disorders of Hematopoiesis and Immunity

Biology of Blood and Marrow Transplantation

Volumn 13, Issue SUPPL. 1, 2007, Pages 58-63

  Filipovich, Alexandra H ^a   Bleesing, Jack ^a   Goldman, Fred ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

ALPS (Autoimmune Lymphoproliferative syndrome); DC (Dyskeratosis Congenita); IPEX (Immune dysregulation, Polyendocrinopathy, X linked)

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS;

ARTICLE; AUTOIMMUNE DISEASE; CANCER RISK; CLINICAL PROTOCOL; DISEASE MODEL; DISEASE SEVERITY; DYSKERATOSIS CONGENITA; ENTEROPATHY; GENETIC DISORDER; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DYSREGULATION; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LYMPHOPROLIFERATIVE DISEASE; MICROANGIOPATHY; NONHUMAN; PATHOGENESIS; POLYENDOCRINOPATHY; PROGNOSIS; X CHROMOSOME LINKED DISORDER;

EID: 33846008735     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.10.003     Document Type: Article

References (51)

1. Ochs H.D., Ziegler S.F., and Torgerson T.R. FOXP3 acts as a rheostat of the immune response. Immunol Rev 203 (2005) 156-164
2. Wildin R.S., Smyk-Pearson S., and Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 39 (2002) 537-545
3. Russell W.L., Russell L.B., and Gower J.S. Exceptional inheritance of a sex-linked gene in the mouse explained on the basis that the X/O sex-chromosome constitution is female. Proc Natl Acad Sci USA 45 (1959) 554-560
4. Brunkow M.E., Jeffery E.W., Hjerrild K.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27 (2001) 68-73
5. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27 (2001) 20-21
6. Wildin R.S., Ramsdell F., Peake J., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27 (2001) 18-20
7. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182 (2001) 18-32
8. Mazzolari E., Forino C., Fontana M., et al. A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant 35 (2005) 1033-1034
9. Bacchetta R., Passerini L., Gambineri E., et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 116 (2006) 1713-1722
10. Bindl L., Torgerson T., Perroni L., et al. Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr 147 (2005) 256-259
11. Smyk-Pearson S.K., Bakke A.C., Held P.K., and Wildin R.S. Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes. Clin Exp Immunol 133 (2003) 193-199
12. Baud O., Goulet O., Canioni D., et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 344 (2001) 1758-1762
13. Rao A, Kamani N, Filipovich A, et al. Successful bone marrow transplantation for IPEX syndrome following reduced intensity conditioning. Blood. In press.
14. Lenardo M., Chan K.M., Hornung F., et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17 (1999) 221-253
15. Bleesing J.J. Autoimmune lymphoproliferative syndrome (ALPS). Curr Pharm Des 9 (2003) 265-278
16. Rieux-Laucat F., Fischer A., and Deist F.L. Cell-death signaling and human disease. Curr Opin Immunol 15 (2003) 325-331
17. Straus S.E., Jaffe E.S., Puck J.M., et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98 (2001) 194-200
18. Sneller M.C., Straus S.E., Jaffe E.S., et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest 90 (1992) 334-341
19. Fisher G.H., Rosenberg F.J., Straus S.E., et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81 (1995) 935-946
20. Rieux-Laucat F., Le Deist F., Hivroz C., et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268 (1995) 1347-1349
21. Jackson C.E., Fischer R.E., Hsu A.P., et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet 64 (1999) 1002-1014
22. Holzelova E., Vonarbourg C., Stolzenberg M.C., et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 351 (2004) 1409-1418
23. Bleesing J.J. Sorting out the causes of ALPS. J Pediatr 147 (2005) 571-574
24. Rössler J., Enders A., Lahr G., et al. Identical phenotype in patients with somatic and germ line CD95 mutations requires a new diagnostic approach to autoimmune lymphoproliferative syndrome. J Pediatr 147 (2005) 691-694
25. van der Werff Ten Bosch J., Schotte P., Ferster A., et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol 117 (2001) 176-188
26. Rao V.K., Dugan F., Dale J.K., et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 129 (2005) 534-538
27. Heelan B.T., Tormey V., Amlot P., Payne E., Metha A., and Webster A.D. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome. Br J Haematol 118 (2002) 1078-1081
28. Teachey B.T., Obzut D.A., Axsom K., et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 108 6 (2006) 1965-1971
29. Benkerrou M., Le Deist F., de Villartay J.P., et al. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol 27 (1997) 2043-2047
30. Sleight B.J., Prasad V.S., DeLaat C., et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant 22 (1998) 375-380
31. Bleesing J.J., Brown M.R., Straus S.E., et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood 98 (2001) 2466-2473
32. Bidere N., Su H.C., and Lenardo M.J. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 24 (2006) 321-352
33. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohaemopoietic chimerism and graft-versus lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet 353 (1999) 1755-1759
34. Carella A.S., Giralt S., and Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 85 (2000) 304-313
35. Kapelushnik J., Mandel H., Varadi G., and Nagler A. Fludarabine-based protocol for haploidentical peripheral blood stem cell transplantation in Hurler syndrome. J Pediatr Hematol Oncol 22 (2000) 433-436
36. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1 (1998) 2817-2824
37. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
38. Childs R., Clave R., Tsidale J., Plante M., Hensel N., and Barrett J. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94 (1999) 3234-3241
39. Perkins D.L., Michaelson J., and Marshak-Rothstein A. The lpr gene is associated with resistance to engraftment by lymphoid but not erythroid stem cells from normal mice. J Immunol 138 (1987) 466-469
40. van Den Brink M.R., Moore E., Horndasch K.J., et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J Immunol 164 (2000) 469-480
41. Heiss N.S., Knight S.W., Vulliamy T.J., et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 19 (1998) 32-38
42. Vulliamy T., Marrone A., Goldman F., et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413 (2001) 432-435
43. Levy M.Z., Allsopp R.C., Futcher A.B., Greider C.W., and Harley C.B. Telomere end-replication problem and cell aging. J Mol Biol 225 (1992) 951-960
44. Morrison S.J., Prowse K.R., Ho P., and Weissman I.L. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity 5 (1996) 207-216
45. Vulliamy T., Marrone A., Szydlo R., Walne A., Mason P.J., and Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 36 (2004) 447-449
46. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 110 (2000) 768-779
47. Nobili B., Rossi G., De Stefano P., et al. Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen. Br J Haematol 119 (2002) 573-574
48. Yabe M., Yabe H., Hattori K., et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 19 (1997) 389-392
49. Rocha V., Devergie A., Socie G., et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Hematol 103 (1998) 243-248
50. Beasley M.A., Singhal V., Klingelhutz A.J., Akabogu I., and Goldman F.D. Association of telomere length in dyskeratosis congenita lymphocytes with increased sensitivity to radiation and anti-mitotic agents. Blood 104 (2004) 775a
51. Dror Y., Freedman M.H., Leaker M., et al. Low-intensity hematopoietic stem cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 31 (2003) 847-850